|
Catalogue Number
|
156372 |
|
Antigen/Gene or Protein Targets
|
PKCα
|
|
Parental Line
|
MCF-7
|
|
Synonyms
|
MCF7
|
|
Host
|
Human
|
|
Tissue
|
Breast
|
|
Disease Keywords
|
Breast Cancer; Tamoxifen Resistance
|
|
Model
|
Cancer Model
|
|
Relevance
|
Approximately 70% of breast cancer patients have estrogen receptor positive (ER+) tumors. The selective estrogen receptor modulator (SERM), tamoxifen, and aromatase inhibitors (AIs) represent first-line treatment for ER+ patients however, up to 50% of patients either do not respond or acquire resistance within 5 years of treatment. The MCF7-PKCa cell line was engineered to exogenously overexpress Protein Kinase C alpha (PKCα) which rendered it resistant to tamoxifen. MCF7-PKCα represents a valuable model for tamoxifen resistance and for screening the effectiveness of alternatives.
|
|
Research Area
|
Cancer, Drug Discovery & Development
|
|
Notes
|
Engineered to over-express PKCα.
|
